AUROBAC THERAPEUTICS’ R&D strategy encompasses patient- and pathogen-targeted programs designed to tackle both the causes and consequences of serious bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia, sepsis and septic shock. Central to this approach is the adoption of innovative diagnostic strategies aimed at facilitating patient stratification and optimizing treatment outcomes.
AUROBAC THERAPEUTICS aims to cover the entire value chain of projects, including research and development, clinical trials, registration, and commercialization.
ATX101New Chemical Entity
First-in-class therapeutic targeting the loss of vascular integrity in septic shock
Target indication: Treatment of early septic shock to prevent progression and improve outcome
Partner
ATX4Lead ID to Preclinical
Engineered Biologics at various stages between Lead Identification to Preclinical
Target indication: Treatment of infections caused by Gram-negative pathogens
Partner
ATX2Hit Discovery Program
Antimicrobial peptides discovered through machine-learning algorithms
Target indication: 2nd line precision treatment of infections caused by Gram-negative pathogens
Partner
ATX5New Chemical Entity
New MedChem Program – Undisclosed Target
Target indication: Treatment of infections caused by Gram-negative pathogens
Partner
ATX3Hit Discovery Collaboration
Natural Products – Mining microbial diversity to discover new scaffolds
Target indication: Treatment of infections caused by Gram-negative pathogens
Partner
If you have a breakthrough that you think will make an interesting collaboration, we would like to hear from you.